Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1763-1767

  Aebi, Stefan ^a,b   Fink, Daniel ^a   Gordon, Robert ^a   Kim, Heung Ki ^a   Zheng, Hua ^a   Fink, J Lynn ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; PACLITAXEL; TIOGUANINE;

ARTICLE; BASE MISPAIRING; CELL MEMBRANE RESISTANCE; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA SEQUENCE; DRUG RECEPTOR BINDING; GENE MUTATION; HUMAN; HUMAN CELL; METHYLATION; MUTATION RATE; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARRIER PROTEINS; CISPLATIN; COLORECTAL NEOPLASMS; CYCLOPHOSPHAMIDE; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; MELPHALAN; METHYLNITRONITROSOGUANIDINE; MUTAGENESIS; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PACLITAXEL; PROTO-ONCOGENE PROTEINS; THIOGUANINE; TUMOR CELLS, CULTURED;

EID: 0030819872     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Fishel, R., and Kolodner, R. D. Identification of mismatch repair genes and their role in the development of cancer. Curr. Opin. Genet. Dev., 5: 382-395, 1995.
2. Kat, A., Thilly, W. G., Fang, W. H., Longley, M. J., Li, G. M., and Modrich, P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. USA, 90: 6424-6428, 1993.
3. Reitmair, A. H., Schmits, R., Ewel, A., Bapat, B., Redston, M., Mitri, A., Waterhouse, P., Mittrucker, H. W., Wakeham, A., Liu, B., Thomason, A., Griesser, H., Gallinger, S., Ballhausen, W. G., Fishel, R., and Mak, T. W. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat. Genet., 11: 64-70, 1995.
4. Aquilina, G., Biondo, R., Dogliotti, E., and Bignami, M. Genetic consequences of tolerance to methylation DNA damage in mammalian cells. Carcinogenesis (Lond.), 14: 2097-2103, 1993.
5. Griffin, S., Branch, P., Xu, Y. Z., and Karran, P. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry, 33: 4787-4793, 1994.
6. Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R. M., and Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56: 1374-1381, 1996.
7. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996.
8. Drummond, J. T., Anthoney, A., Brown, R., and Modrich, P. Cisplatin and Adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem., 271: 19645-19648, 1996.
9. Bhattacharyya, N. P., Skandalis, A., Ganesh, A., Groden, J., and Meuth, M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 91: 6319-6323, 1994.
10. Hess, P., Aquilina, G., Dogliotti, E., and Bignami, M. Spontaneous mutations at aprt locus in a mammalian cell line defective in mismatch recognition. Somat. Cell. Mol. Genet., 20: 409-421, 1994.
11. Baker, S. M., Plug, A. W., Prolla, T. A., Bronner, C. E., Harris, A. C., Yao, X., Christie, D. M., Monell, C., Arnheim, N., Bradley, A., Ashley, T., and Liskay, R. M. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat. Genet., 13: 336-342, 1996.
12. Andrews, P. A., Jones, J. A., Varki, N. M., and Howell, S. B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun., 2: 93-100, 1990.
13. Boyer, J. C., Umar, A., Risinger, J. I., Lipford, J. R., Kane, M., Yin, S., Barrett, J. C., Kolodner, R. D., and Kunkel, T. A. Microsatellite instability, mismatch repair deficiency, and genetic defects inhuman cancer cell lines. Cancer Res., 55: 6063-6070, 1995.
14. Carethers, J. M., Hawn, M. T., Chauhan, D. P., Luce, M. C., Marra, G., Koi, M., and Boland, C. R. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanidine. J. Clin. Invest., 98: 199-206, 1996.
15. Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res., 54: 4308-4312, 1994.
16. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
17. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Woodrich, M., Campbell, H., Mayo, J., and Boyd, M. Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell line. J. Natl. Cancer Inst., 83: 757-766, 1990.
18. Hawn, M. T., Umar, A., Carethers, J. M., Marra, G., Kunkel, T. A., Boland, C. R., and Koi, M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res., 55: 3721-3725, 1995.
19. Gately, D. P., and Howell, S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer, 67: 1171-1176, 1993.
20. Markowitz, S., Wing, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., Brattain, M., and Willson, J. K. V. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science (Washington DC), 268: 1336-1338, 1995.
21. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
22. Liu, L., Markowitz, S., Willson, J. K. V., and Gerson, S. L. Mismatch repair mutator phenotype confers resistance to temozolomide in human colon cancer cell lines. Proc. Am. Assoc. Cancer Res., 37: 365, 1996.
23. D'Atri, S., Graziani, G., Lacal, P. M., Tentori, L., Bonmassar, E., Pagani, E., and Jiricny, J. Role of mismatch repair in apoptosis induced by methyltriazenes. Proc. Am. Assoc. Cancer Res., 38: 1, 1997.
24. Rode, P., Kupiec, N., Teicher, B. A., Emi, Y., and Bubley, G. The effect of a homozygous hMLH1 mutation of antitumor alkylating agent sensitivity. Proc. Am. Assoc. Cancer Res., 37: 380, 1996.
25. 4-methylthymidine, or the cisplatin d(GpG) adduct. Proc. Natl. Acad. Sci. USA, 93: 6443-6447, 1996.
26. Mello, J. A., Acharya, S., Fishel, R., and Essigman, J. M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. Biol., 3: 579-589, 1996.
27. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol., 36: 191-218, 1994.
28. Fink, D., Zheng, H., Nebel, S., Lin, R. T., Aebi, S., MacLeod, C. L., and Howell, S. B. Resistance to cisplatin but not to oxaliplatin in DNA mismatch repair deficient xenografts in athymic nude mice. Proc. Am. Soc. Clin. Oncol., 33: 531a, 1997.